Skip to main content
Premium Trial:

Request an Annual Quote

Framingham Study Gets Funds to Continue

The long-running Framingham Heart Study has received a $38 million grant to continue for another six years, the Boston Globe reports.

"This will let us do deep phenotyping," Vasan Ramachandran, the study's principal investigator at Boston University tells the Globe. "Technology has changed. When this study began, we could measure a few proteins circulating in the blood. Now we have screening where we can measure up to 1,300 proteins."

The study began in 1948 when it recruited 5,209 men and women between ages of 30 and 62 to examine factors that influence risk of heart disease, and, as BU notes in a press release, contributed to findings that smoking and obesity contribute to cardiovascular disease risk, while physical activity may be protective. It adds that the study is now following the children and grandchildren of the original enrollees.

With these new funds, Ramachandran says the study will examine the contribution of aging to health and disease, the Globe adds, noting that it will focus not only on the heart, but also the brain and liver.

The Scan

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.